Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]Ga-PentixaFor PET for Multiple Myeloma Staging
NCT05321862Phase 2Withdrawn
- Sponsor
- CHU de Nantes
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentixafor in multiple myeloma (MM), sponsored by CHU de Nantes. Primary endpoint: Sensitivity of [68Ga]Ga-PentixaFor-PET at 6 months. Planned start Mar 2023; status: withdrawn.
02
Drugs
pentixafor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05321862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05321862.